All News
Filter News
Found 1,104 articles
-
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
6/10/2022
MorphoSys AG is presenting data from multiple analyses of the ongoing MANIFEST study, an open-label Phase 2 clinical trial of pelabresib, an investigational BET inhibitor, in patients with myelofibrosis, a rare bone marrow cancer for which only limited treatment options are available.
-
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China
5/26/2022
InnoCare Pharma announced that it has received approval to conduct a single-arm, open-label, multicenter phase II clinical trial evaluating the safety and efficacy of tafasitamab in combination with lenalidomide by China’s National Medical Products Administration for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation.
-
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
5/26/2022
Incyte announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 Congress.
-
MorphoSys AG Reports Outcome of Annual General Meeting 2022
5/18/2022
MorphoSys AG announced that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual General Meeting which took place on Wednesday, May 18, 2022.
-
MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
5/12/2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced that new data on pelabresib and tafasitamab, marketed in the U.S. as Monjuvi® and in Europe as Minjuvi®, will be presented during the 2022 American Society of Clinical Oncology Annual Meeting (ASCO 2022) in Chicago from June 3 – 7, 2022 and the 2022 European Hematology Association Hybrid Congress (EHA 2022) in Vienna, Austria, from June 9 – 12, 2022.
-
Xencor Reports First Quarter 2022 Financial Results
5/5/2022
Xencor, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a review of recent business and clinical highlights.
-
MorphoSys AG Reports First Quarter 2022 Financial Results
5/4/2022
Monjuvi® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth.
-
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
5/3/2022
Incyte (Nasdaq:INCY) today reports 2022 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.
-
Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.
-
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
4/28/2022
MorphoSys AG will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST.
-
Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A
4/13/2022
Today, Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies.
-
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
3/29/2022
I-Mab announced financial results for the 12 months ended December 31, 2021, and provided key business updates.
-
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
3/22/2022
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/16/2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and full year 2021.
-
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
3/15/2022
MorphoSys U.S. Inc. announced that the National Comprehensive Cancer Network Clinical Practice Guidelines ) in Oncology for B-cell Lymphomas have been updated, and the designation for Monjuvi in combination with lenalidomide is now a Preferred Regimen for second-line therapy in patients with Diffuse Large B-cell Lymphoma who are not candidates for transplant.
-
The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.
-
MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021
3/10/2022
MorphoSys AG announces that it will account for a non-cash impairment charge on goodwill in the amount of approximately € 231 million.
-
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
3/10/2022
MorphoSys AG ; will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET.
-
The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.
-
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
2/23/2022
Xencor, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a review of recent business and clinical highlights.